Article
The current state of the art and future trends in RAS-targeted cancer therapies.
Nature reviews. Clinical oncology - 1 Oct 2022
Punekar Salman R, Velcheti Vamsidhar, Neel Benjamin G, Wong Kwok-Kin
Abstract excerpt
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered 'undruggable' owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state. Some of these inhibitors have proven efficacy in...
Topics
- Humans
- Mutation
- Neoplasms
- Proto-Oncogene Proteins p21(ras)
- Signal Transduction
- Tumor Microenvironment